ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.30
-0.49 (-7.22%)
As of 12:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.79
Open6.76
Bid6.27 x 900
Ask6.30 x 800
Day's Range6.10 - 6.79
52 Week Range5.59 - 15.14
Volume349,363
Avg. Volume579,915
Market Cap111.031M
Beta (3Y Monthly)4.01
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.40
Trade prices are not sourced from all markets
  • Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
    Zacks3 hours ago

    Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • GlobeNewswire11 days ago

    Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Zynerba’s Chief Executive Officer, will present a company overview at the 2018 BIO Investor Forum. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Beverage Giants Buying Into The Cannabis Boom
    Oilprice.com19 days ago

    Beverage Giants Buying Into The Cannabis Boom

    The beverage sector is one of the most profitable in the markets, and now these billion-dollar giants are getting in on the next great North American industry

  • InvestorPlace21 days ago

    2 Marijuana Biotechs to Watch

    On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.

  • ACCESSWIRE21 days ago

    The Hottest CBD Stocks

    HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...

  • GlobeNewswire26 days ago

    Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2018 Cantor Global Healthcare conference. The presentation will take place on October 1, 2018 at 2:55 PM EDT at the InterContinental New York Barclay Hotel. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Benzingalast month

    Cantor Fitzgerald's 7 Buys For 7 Biotechs

    Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...

  • Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
    Zackslast month

    Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • ACCESSWIRElast month

    CBD Stocks Set to Explode

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...

  • What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
    Simply Wall St.last month

    What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?

    I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., L.L.C. on September 5, 2018 at 8:45 AM EDT at the St. Regis New York. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

  • Zynerba Pharmaceuticals Continues Its 3-Day Rally
    InvestorPlace2 months ago

    Zynerba Pharmaceuticals Continues Its 3-Day Rally

    The stock went from its closing price of $6.80 on Tuesday and finished the day off sitting at $8.00. This represents an 17%-increase for Zynerba Pharmaceuticals on Wednesday. Now the rally for ZYNE stock is still going strong on Thursday, Aug. 30, 2018.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call

  • The Worst-Performing Marijuana Stocks in July
    Motley Fool2 months ago

    The Worst-Performing Marijuana Stocks in July

    Talk about buzzkills! These five pot stocks all fell by at least 19% last month.

  • Associated Press3 months ago

    Zynerba: 2Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 89 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

    DEVON, Pa., Aug. 02, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today ...

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher will present a company overview at the 38th Annual Canaccord Genuity Growth Conference on August 8, 2018 at 4:00 PM EDT at the InterContinental Boston. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire3 months ago

    Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update

    DEVON, Pa., July 31, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host ...

  • ACCESSWIRE3 months ago

    This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up

    CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.

  • InvestorPlace3 months ago

    Market Roasts Shares of Zynerba Pharmaceuticals

    Just as shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) were on the way to rebounding back to the $10 level, the stock fell on Friday after the company announced a share issuance. With a 25-percent cut in the ZYNE share price, is the sell-off in this micro-cap biotechnology firm overdone? Zynerba announced a tiny, $32.5 million public offering of its shares: 4.062 million shares at $8 each.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...